Insight Molecular Diagnostics shareholders approve 1,750,000-share increase to equity plan

• Insight Molecular Diagnostics held its annual shareholder meeting on June 11, 2026.
• Shareholders backed an amendment to the 2018 Equity Incentive Plan, adding 1,750,000 shares for equity awards; total authorization rose to 5,550,000 shares.
• The plan amendment was authorized by shareholders; the filing does not confirm any equity awards have been issued under the expanded share pool.
• CBIZ CPAs P.C. was ratified as independent registered public accounting firm for the year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029078), on June 17, 2026, and is solely responsible for the information contained therein.